Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 48,916 shares, a decrease of 38.8% from the May 14th total of 79,876 shares. Based on an average trading volume of 37,619 shares, the short-interest ratio is currently 1.3 days. Approximately 2.8% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock opened at $4.20 on Monday. Quoin Pharmaceuticals has a one year low of $4.10 and a one year high of $41.80. The stock has a market capitalization of $8.43 million, a PE ratio of -0.14 and a beta of 1.56. The business’s fifty day moving average is $5.60 and its 200 day moving average is $9.02.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.77) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.40. As a group, sell-side analysts expect that Quoin Pharmaceuticals will post -7.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of QNRX. GAMMA Investing LLC lifted its holdings in Quoin Pharmaceuticals by 649.6% in the fourth quarter. GAMMA Investing LLC now owns 2,084 shares of the company’s stock valued at $30,000 after acquiring an additional 1,806 shares during the period. Aberdeen Group plc bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $1,082,000. AIGH Capital Management LLC bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $712,000. Simplify Asset Management Inc. bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $252,000. Finally, ADAR1 Capital Management LLC bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $840,000. Institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.